论文部分内容阅读
1商品名Inavir2开发与上市厂商2009年3月日本第一三共制药从澳大利亚BiotaHoldings制药公司获得了本品在日本的上市销售许可权。2010年9月首次在日本上市。3适应证本品为第二代吸入型长效神经氨酸酶抑制剂,用于治疗和预防流感病毒引起的感染症状。4药理
1 Product Name Inavir2 Development and Listing Vendor March 2009 Japan First Sanyo acquired marketing permission for the product in Japan from BiotaHoldings Australia. September 2010 debut in Japan. 3 Indications This product is the second generation of inhaled long-acting neuraminidase inhibitors for the treatment and prevention of influenza virus-induced infection symptoms. 4 pharmacology